SEC – ‘UPLOAD’ from 3/17/21 re: Aldeyra Therapeutics, Inc. – ‘TEXT-EXTRACT’

On:  Wednesday, 3/17/21, at 5:30pm ET   ·   Delayed-Release:  Filing ¶  –  Release Delayed   ·   Accession #:  0-21-3224

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Delayed-Release Comment or Other Letter from the SEC
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: LETTER      Comment or Other Letter from the SEC                 PDF     28K 
 2: TEXT-EXTRACT  Comment or Other Letter from the SEC - PDF's         1      5K 
                Text                                                             

‘TEXT-EXTRACT’   —   Comment or Other Letter from the SEC – PDF’s Text

United States securities and exchange commission logo                           

March 17, 2021              

Todd C. Brady, M.D., Ph.D.                                        
Chief Executive Officer                                           
Aldeyra Therapeutics, Inc.                                        
131 Hartwell Avenue, Suite 320                                    
Lexington, MA 02421                                               

                                           Re: Aldeyra
Therapeutics, Inc.                                                              
                                                    Registration
Statement on Form S-3                                                           
                                                       Filed March 11,
2021                                                                            
                                                           File No. 333-254175

Dear Dr. Brady:                                                   

        This is to advise you that we have not reviewed and will not
review your registration                                                        
statement.                                                        

      Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you                                                     
      that the company and its management are responsible for the accuracy and
adequacy of their                                                               
     disclosures, notwithstanding any review, comments, action or absence of
action by the staff.                                                            

                                                     Please contact Ada D.
Sarmento at 202-551-3798 with any questions.                                    

Sincerely,                  

   Division of Corporation Finance

Office of Life Sciences     
     cc:                                              Keith J. Scherer, Esq.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘UPLOAD’ Filing		Date		Other Filings
Filed on:		3/17/21		UPLOAD
		3/11/21		10-K,  8-K,  S-3,  S-8,  UPLOAD
				List all Filings